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The mechanism by which c-Jun N-terminal protein kinase (JNK) promotes tissue injury is poorly un-
derstood. Thus we aimed at studying the roles of JNK and its phospho-target proteins in mouse models of
acute liver injury. Young male mice were exposed to a single dose of CCl4 (50 mg/kg, IP) and euthanized
at different time points. Liver histology, blood alanine aminotransferase, and other enzyme activities
were measured in CCl4-exposed mice without or with the highly-speciﬁc JNK inhibitors. Phosphoproteins
were puriﬁed from control or CCl4-exposed mice and analyzed by differential mass-spectrometry fol-
lowed by further characterizations of immunoprecipitation and activity measurements. JNK was acti-
vated within 1 h while liver damage was maximal at 24 h post-CCl4 injection. Markedly increased
phosphorylation of many mitochondrial proteins was observed between 1 and 8 h following CCl4 ex-
posure. Pretreatment with the selective JNK inhibitor SU3327 or the mitochondria-targeted antioxidant
mito-TEMPO markedly reduced the levels of p-JNK, mitochondrial phosphoproteins and liver damage in
CCl4-exposed mice. Differential proteomic analysis identiﬁed many phosphorylated mitochondrial pro-
teins involved in anti-oxidant defense, electron transfer, energy supply, fatty acid oxidation, etc. Alde-
hyde dehydrogenase, NADH-ubiquinone oxidoreductase, and α-ketoglutarate dehydrogenase were
phosphorylated in CCl4-exposed mice but dephosphorylated after SU3327 pretreatment. Consistently,
the suppressed activities of these enzymes were restored by SU3327 pretreatment in CCl4-exposed mice.
These data provide a novel mechanism by which JNK, rapidly activated by CCl4, promotes mitochondrial
dysfunction and acute hepatotoxicity through robust phosphorylation of numerous mitochondrial pro-
teins.
Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. . Introduction
Epidemiological studies revealed that many people suffer from
acute liver failure, which can be produced by overdose of potentiallyaccess article under the CC BY-NC
P, acetaminophen; CYP2E1,
ated kinase; α-KGDH, α-ke-
NK, c-Jun N-terminal protein
permeability transition;
e-oxidoreductase; p38K, p38
e dehydrogenase; TNF-α, tu-
il.com (A. Banerjee),
cript.toxic compounds such as acetaminophen (APAP), cocaine, and binge
alcohol (ethanol). For instance, over 56,000 emergency room visits
with more than 400 deaths per year are due to APAP-induced acute
liver injury in the United States alone [1]. Over-exposure to these
substances can cause cell/tissue injury and sudden deaths in hu-
mans and experimental models [1,2 and references within] espe-
cially in combination with alcohol through additive or synergistic
interactions [3,4]. However, the molecular mechanisms of acute li-
ver damage by these agents remain elusive because of the con-
ﬂicting results.
Carbon tetrachloride (CCl4) is a hepatotoxic solvent widely used
to study the mechanisms for acute liver injury and chronic ﬁbrosis
in experimental models [5–8]. The majority of CCl4 is metabolized
by the ethanol-inducible CYP2E1 and thus Cyp2e1-null mice are
protected from CCl4-induced liver damage [9]. Following CYP2E1-
related metabolism, free radical metabolites of CCl4 attack cellular
membranes, producing lipid peroxides, leading to severe necrosis
in the pericentral regions of the liver [5,6]. However, despite the-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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virtually unknown whether CCl4 can promote liver injury through
modifying the phosphorylation of cellular proteins.
Mitogen-activated protein kinases (MAPKs) are cell signal-re-
lated kinases known to regulate cell death and growth, depending
on the cellular contexts and their temporal ﬂuctuations. It is well-
established that there are three major MAPKs: c-Jun N-terminal
protein kinase (JNK), p38 kinase (p38K), and extracellular signal-
regulated kinase (ERK). In general, activation of JNK and p38K is
related to cell death signaling pathways while ERK activation is
involved in cell survival and proliferation [10]. JNK-related sig-
naling pathways are also known to be associated with liver phy-
siology and pathology [11]. For instance, JNK-mediated cell da-
mage has been observed with many toxic compounds such as
APAP [12–14], staurosporine [15] and UV exposure [15] as well as
under pathological conditions including ischemia-reperfusion in-
jury [16]. Mendelson et al. [17] reported that JNK was potently
activated while ERK and p38K remained unchanged and de-
creased, respectively, following CCl4 treatment, suggesting a role
of JNK in promoting hepatotoxicity. In contrast, other investigators
reported that JNK activation was not critical in CCl4-mediated
acute liver injury, compared to the important role of JNK in APAP-
induced liver damage [12,13]. Therefore, the underlying mechan-
ism by which activated (phosphorylated) p-JNK promotes cell or
liver damage is poorly understood.
We recently reported that CCl4 rapidly activated p-JNK, which
was translocated to mitochondria and phosphorylated mitochon-
drial aldehyde dehydrogenase (ALDH2), an anti-oxidant enzyme,
leading to its inactivation and accumulation of lipid peroxides
following CCl4 exposure [18]. In addition, a previous report with
isolated mitochondrial proteins showed that activated p-JNK
phosphorylated other mitochondrial enzymes such as pyruvate
dehydrogenase (PDH) E1α and β subunits, ATP synthase α and β
subunits, and heat shock proteins (Hsp60 and Hsp70) [19]. Based
on these reports, we hypothesized that p-JNK, rapidly activated at
early hours after CCl4 exposure, translocates to mitochondria,
phosphorylates many mitochondrial proteins and suppresses their
functions, contributing to mitochondrial dysfunction and necrotic
liver damage. However, it is poorly understood how many other
proteins are phosphorylated by p-JNK and whether these phos-
phoproteins are functionally altered to contribute to CCl4-induced
liver injury. Thus, we investigated the mechanism of acute hepa-
totoxicity by determining the role of JNK in promoting mi-
tochondrial dysfunction and liver necrosis. For this purpose, we
speciﬁcally aimed to identify and characterize mitochondrial JNK-
target proteins in the absence or presence of the speciﬁc JNK in-
hibitors. To further support the role of JNK in causing hepato-
toxicity, we also evaluated the histological and biochemical mea-
surements of CCl4-exposed Cyp2e1-null mice as compared to those
of the corresponding wild-type (WT) counterparts.2. Materials and methods
2.1. Chemicals and other materials
NADþ and propionyl aldehyde were purchased from Sigma (St.
Louis, MO, USA). Speciﬁc antibodies to c-Jun, phospho-c-Jun
(Ser63), JNK, phospho-JNK (Thr183/Tyr185), p38 kinase, phospho-
p38 kinase (Thr180/Tyr182), ERK, phospho-ERK (Thr202/Tyr204),
phospho-Ser-Pro, Bax, and cytochrome C were purchased from
Cell Signaling Technology, Inc (Beverly, MA). Phosphoprotein-
puriﬁcation kit including the metal-afﬁnity columns was obtained
from Qiagen (Valencia, CA). ProQ-Diamond phosphoprotein
staining reagent was from Invitrogen (Eugene, OR). Speciﬁc goat
polyclonal antibodies to mitochondrial ALDH2, 75-kDa subunit(Ndufs1) of NADH-ubiquinone oxidoreductase (complex I), cyto-
chrome c oxidase (complex IV), ATP synthase beta-subunit (ATP5B,
complex V), lamin, α-tubulin, peroxiredoxin, and α-ketoglutarate
dehydrogenase (α-KGDH) were obtained from Santa Cruz Bio-
technology, Inc (Santa Cruz, CA, USA). Speciﬁc antibodies to 3-ni-
tro-Tyr (3-NT) were from Abcam (Cambridge, MA) while speciﬁc
anti-HNE-adducts were purchased from Calbiochem (La Jolla, CA,
USA). Speciﬁc JNK inhibitors SU3327 [20] and BI-78D3 [21] were
purchased from Tocris Bioscience (Bristol, United Kingdom). Both
SU3327 and BI-78D3 inhibit JNK activity through blockade of
protein-protein interaction between JNK and its scaffolding pro-
tein JNK-interacting protein-1 (JIP-1). In addition, another report
suggested that BI-78D3 can inhibit JNK activity through covalent
modiﬁcation of Cys163 of JNK [22]. Other agents including the JNK
inhibitor SP600125 and the mitochondria-targeted antioxidant
mito-TEMPO [2-(2,2,6,6-tetramethylpiperidine-1-oxyl-4-ylamino)
2-oxoethyl]tripphenylphosphenium chloride [23] were obtained
from Sigma (St. Louis, MO, USA).
2.2. Animal treatment and histological analysis
Age and gender-matched young male NCI-WT mice (Svj-129
background) and Cyp2e1-null mice [24], kindly provided by Dr.
Frank J. Gonzalez (National Cancer Institute, Bethesda, MD), were
used and kept in a 12 h light-dark cycle with food and water ad
libitum in accordance with NIH guidelines. After a single in-
traperitoneal injection of CCl4 (50 mg/kg as 0.5% in corn oil), the
WT and Cyp2e1-null mice (n¼4–5/group) were euthanized at the
indicated time points. Each JNK inhibitor (10 mg/kg, a single ip
injection, n¼4–5/group) was prepared as 1.25 mg/mL with 10%
Solutol-HS15 in PBS, and administered 30 min prior to CCl4 in-
jection. Mito-TEMPO was dissolved in sterile saline and adminis-
tered by a single dose at 5 mg/kg ip 30 min before CCl4 treatment.
A portion from the largest lobe of each liver, obtained from
CCl4-exposed WT in the absence or presence of JNK inhibitors and
Cyp2e1-null mice collected at different time points, was ﬁxed in
10% neutral buffered formalin. After parafﬁn embedding and the
cutting of 4 mm slices, all sections were stained with hematoxylin
and eosin (H&E), as described [24]. Histological evaluation was
performed in a blinded manner.
2.3. Mass spectrometry analysis of puriﬁed phosphorylated proteins
To afﬁnity-purify phosphorylated proteins, 250 mg of mi-
tochondrial proteins from WT mice at 2 h post-injection of CCl4,
were subjected to a metal-afﬁnity column (Qiagen, Valencia, CA)
by following the manufacturer’s instructions. The puriﬁcation
procedures for vehicle-control (control) and CCl4-exposed sam-
ples, respectively, were repeated at least ﬁve times to collect suf-
ﬁcient amounts of puriﬁed phosphoproteins. Puriﬁed phospho-
proteins were resolved on 1-D SDS-PAGE. Each gel lane was cut
with a razor blade into 13 bands, transferred into clean tubes and
subjected to further digestion with sequencing grade trypsin
(Promega, Madison, WI, USA). In-gel digestion of protein gel slices,
nanoﬂow reversed-phase liquid chromatography (nanoRPLC)–
tandem mass spectrometry (MS/MS) and protein identiﬁcation
analyses were performed as recently described [25]. For mass
spectrometry analysis, each sample was re-dissolved in 15 μL of
0.1% formic acid and 5 μL was injected onto a 9 cm75 μm i.d. in-
house packed fused silica capillary electrospray ionization (ESI)
C18 column, which was coupled online to a liner ion trap mass
spectrometer (LTQ XL, Thermo Electron, San Jose, CA). Peptide
separation was performed at a ﬂow rate of 250 nL/min using a
step gradient of 2–42% solvent B (0.1% formic acid in acetonitrile)
for 40 min, 42–98% solvent B for 10 min, and 98% solvent B for
5 min. Both solvents A (0.1% formic acid in water) and B were
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nologies, Palo Alto, CA). The mass spectrometer was operated in a
data dependent mode in which each full MS scan was followed by
7 MS/MS scans where the 7 most abundant peptide molecular ions
were dynamically selected from the prior MS scan for collision-
induced dissociation (CID) using a normalized collision energy of
35%. The raw MS/MS data were searched using the SEQUEST
cluster running under BioWorks (Rev. 3.3.1 SP1) (Thermo Electron,
San Jose, CA) against a mouse IPI proteome database downloaded
from the European Bioinformatics Institute (EBI) (http://www.ebi.
ac.uk) for the identiﬁcation of peptides and proteins within each
gel band. To identify phosphoproteins from CCl4-exposed samples,
only the proteins with two or more unique peptides were con-
sidered conﬁdently as legitimate identiﬁcations. Subtraction of
phosphoproteins between control and CCl4-exposed samples was
performed to further identify the proteins preferentially phos-
phorylated by CCl4 exposure [26] using the similar method de-
scribed previously [27]. For this analysis, the area of extracted ion
chromatogram of each identiﬁed peptide was calculated. The total
area of all the peptides identiﬁed from the same protein was then
normalized by the total area of all the proteins identiﬁed within
the sample (13 gel bands for each sample) and expressed as parts
per million (ppm) that referred to normalized intensity. After
normalization, a ratio was calculated for each protein between the
CCl4-exposed and the control samples. A ratio of CCl4/controlZ1.5
was used to identify phosphoproteins following CCl4-exposure,
since CCl4 treatment markedly increased phosphorylation of mi-
tochondrial proteins compared to those of control. The quantiﬁed
mitochondrial phosphoproteins were further analyzed using Me-
taCore (GeneGo, St. Joseph, MI, USA) software for molecular toxi-
city analysis according to the method described previously [28]
and for veriﬁcation of mitochondrial localization of proteins in
conjunction with UniProt Knowledgebase (http://www.uniprot.
org).
2.4. SDS-PAGE and immunoblot analysis
Mitochondrial fractions were prepared from pooled mouse li-
vers (n¼4–5/group) from the different treatment groups, as pre-
viously described [29,30]. CHAPS-solubilized mitochondrial pro-
teins were dissolved in Laemmli SDS-sample buffer and electro-
phoresed as per manufacturer's recommendations (Bio-Rad, Her-
cules, CA) and subjected to immunoblot analysis with the speciﬁc
antibody to JNK, p-JNK, p-c-Jun, p-Ser-Pro, α-KGDH, ATP5B,
NdufS1, or ALDH2, as indicated. The images were visualized by
enhanced chemiluminescence detection by following the manu-
facturer’s recommendations (Pierce, Rockford, IL, USA).
2.5. Measurements of liver injury parameters, enzyme activities, and
mitochondrial swelling index
Serum alanine aminotransferase (ALT) level from each mouse
was determined by using the automated IDEXX Catachem chem-
istry analyzer system (IDEXX Laboratories, West Brook, ME, USA).
The concentration of lipid peroxides as malondialdehyde (MDA)þ
4-hydroxyalkenal (HAE) (mM) was measured with a commercially
available kit (Oxford Biomedical Research, Oxford, MI, USA) by
following the manufacturer’s protocol. Serum TNFα-levels were
determined by using an ELISA assay kit using the manufacturer’s
protocol (eBioscience, San Diego, CA). Anti-phospho-c-Jun (Ser63)
antibody was used to measure JNK activity by immunoblot ana-
lysis. Mitochondrial and nuclear fractions from each group were
further prepared by subtractive centrifugation, as described
[29,30]. The respective marker proteins for cytosol, mitochondria
and nuclear fractions were shown to verify relative purity of each
fraction (Supplemental Fig. S1). Mitochondrial ALDH2 activity wasmeasured by quantifying the production of NADH at 340 nm, as
previously described [31]. One unit of activity was deﬁned as in-
crease in the absorbance at 340 nm per 0.1 mg protein/min mul-
tiplied by 1000. NADþ-dependent ubiquinone-oxidoreductase
(mitochondrial complex I) activity was measured by the method
previously described [25,32] except that rotenone-containing
samples were measured in parallel. Rotenone-sensitive activities
were normalized with control sample. Activities of α-ketoglutarate
dehydrogenase (α-KGDH) were determined as previously de-
scribed [33] with a modiﬁcation where the reaction volumes were
reduced to 0.2 mL and 0.1 mg mitochondrial proteins were used
for each measurement. One unit of activity was deﬁned as increase
in the absorbance at 340 nm per 0.1 mg protein/min multiplied by
1000. Mitochondrial swelling index was determined as described
[34]. All activities were measured with a Synergy 2 microplate
reader (BioTek, Winooski, VT, USA).
2.6. Immunoprecipitation and immunoblot analysis
Immunoprecipitations of ALDH2, α-KGDH, and NdufS1 (the 75-
kDa subunit of complex I) with the speciﬁc antibody to each
protein were conducted by following the recommended protocol
of Dynabeads (Invitrogen-Life Technologies, Grand Island, NY,
USA). A separate aliquot of mitochondrial proteins (0.5 mg each)
was incubated with 2 mg of antibody-conjugated beads overnight.
The immunoprecipitated proteins were dissolved in Laemmli
buffer for immunoblot analysis using the speciﬁc antibody against
each target protein, as indicated [29].
2.7. Intensity data processing and statistical analysis
The intensity of immuno-recognized protein bands such as
ALDH2, NdufS1 75-kDa subunit of mitochondrial complex I, α-
KGDH, etc on 1-D gels was determined by using a gel digitizing
software (UN-SCAN-IT™, Orem, Utah, USA), as previously de-
scribed [18,25]. All data in this report represent the results from at
least three separate experiments, unless stated otherwise. Statis-
tical analyses were performed using the Student's t test and
po0.05 was considered statistically signiﬁcant. Other methods
and materials not described were the same as reported previously
[25,28–30] or described in the Supplemental ﬁles.3. Results
3.1. Time-dependent JNK activation and its role in CCl4-induced liver
injury
Our results showed that serum ALT levels remained unchanged
until 8 h but markedly increased at 24 h post-CCl4 injection
(Fig. 1A). Consistently, liver histology showed severe pericentral
necrosis observed only at 24 h with little liver injury until 8 h
post-injection (Fig. 1B). CCl4-induced liver damage is related to
increased lipid peroxidation [5,6] and inﬂammation as reﬂected by
elevated levels of TNFα [13,35]. However, our data revealed that
the levels of lipid peroxide measured by MDAþHAE (Fig. 1C) and
serum TNFα (Fig. 1D) remained unchanged up to 8 h, although
they were signiﬁcantly elevated at 24 h post-injection.
Based on rapid JNK activation in CCl4-exposed rats [17,18,36],
we studied the temporal activation of MAPKs in CCl4-exposed
mice by immunoblot analysis. JNK was not activated in corn-oil
(control) group, but potently activated (phosphorylated) at 1 and
2 h post-CCl4 injection (Fig. 2A). Activated p-p38K was detected in
control and its levels did not change (i.e., decreased) until 4 h upon
CCl4 exposure. In contrast, the activated p-ERK was detected in
control while their levels were increased at 1 or 2 h and returned
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Fig. 1. Time-dependent JNK activation and its role in CCl4-induced hepatotoxicity in WT mice. (A) Time-dependent changes in the serum ALT levels and (B) typical H&E-
stained liver slides are presented for each indicated group (magniﬁcation 100 ). Severe necrotic regions of CCl4-exposed samples are marked with broken lines in (B).
(C) Hepatic levels of MDAþHAE, and (D) serum TNF-alpha levels following CCl4 exposure are presented. *, Signiﬁcantly different (po0.05) from the other groups.
Fig. 2. Time-dependent changes in JNK, phosphorylated mitochondrial proteins and JNK activation in CCl4–exposed WT or Cyp2e1-null mice. (A) Whole cell lysates (50 mg/
assay) for indicated samples from WT mice were subjected to immunoblot analysis with the speciﬁc anti-p-JNK, anti-p-p38K, anti-p-ERK, their respective non-phospho-
proteins, anti-c-Jun, or anti-phospho-c-Jun antibody. (B) Mitochondrial lysates (50 mg/lane) for indicated samples from WT mice were subjected to immunoblot analysis
using anti-p-Ser-Pro antibody (left) or anti-p-Thr-Pro antibody (right). Time-dependent changes in the serum ALT levels (C) and JNK activation (D) are presented. Whole cell
lysates (50 mg/assay) for indicated samples (n¼4/each time point) were used to determine JNK activation by immunoblot analysis by using anti-p-JNK antibody (top) and
anti-JNK antibody (bottom).
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phospho-c-Jun was also detected between 2 and 8 h after
CCl4-injection, while c-Jun levels were increased between 1 and
8 h.3.2. JNK target proteins and role of CYP2E1 in CCl4-induced JNK
activation
The levels of total mitochondrial phosphoproteins, detected by
anti-p-Ser-Pro antibody, were markedly increased at 1 h and las-
ted up to 8 h post-CCl4 injection (Fig. 2B, left). However, the levels
of mitochondrial phosphoproteins, detected by anti-p-Thr-Pro
antibody, were very similar between control and CCl4-exposed
samples, except for a few protein bands (Fig. 2B, right). These re-
sults suggest that the number and levels of many phosphorylated
mitochondrial proteins were increased following CCl4 exposure,
although some phosphoproteins existed in control mice.
We also determined the levels of JNK activation at 2 h and the
degrees of acute hepatotoxicity assessed by ALT and histology at
24 h in CCl4-exposed WT and Cyp2e1-null mice. Similar to the
earlier reports [9], ALT levels (Fig. 2C) and histological liver da-
mage (data not shown) were very low in CCl4-exposed Cyp2e1-null
mice even at 24 h, compared to the corresponding WT mice
(Fig. 1A and B, respectively). In addition, the JNK was not activated
in Cyp2e1-null mice at any time points following CCl4 exposure,
compared to the corresponding WT mice (Fig. 2D). These results
suggest that CYP2E1-mediated CCl4 metabolism is required for JNK
activation, which becomes very important in causing acute hepa-
totoxicity usually observed at later time points [11–14,18].0
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analysis by using anti-p-Ser-Pro antibody (top) or anti-ATP5B as a loading control (bott3.3. Protection of CCl4-induced liver injury by new selective JNK
inhibitors
To further determine the critical role of JNK in mitochondrial
dysfunction and liver injury, we evaluated the effects of known
chemical inhibitors of JNK on CCl4-induced JNK activation and
translocation of p-JNK to mitochondria at 2 h and hepatotoxicity at
24 h post-CCl4 injection (n¼4–5/group). Pretreatment with ATP-
competitive JNK inhibitor SP600125 did not prevent CCl4-induced
liver injury determined by serum ALT levels and liver histology
(Supplemental Fig. S2A and B, respectively), unlike the earlier re-
ports [12,37]. However, pretreatment with a new speciﬁc JNK in-
hibitor SU3327 [20] signiﬁcantly protected against CCl4-induced
acute hepatotoxicity assessed by ALT levels (Fig. 3A) and liver
histology (Fig. 3B). Pretreatment with another speciﬁc JNK in-
hibitor BI-78D3 [21,22] also showed similar results of protection
against CCl4-induced hepatotoxicity based on the serum ALT levels
(Supplemental Fig. S2C).
We further studied the effect of SU3327 on JNK activation and
translocation of p-JNK to mitochondria at 2 h post-CCl4 injection. JNK
was potently activated in CCl4-exposed WT mice (Fig. 3C, top panel,
second lane) compared to the control (ﬁrst lane). SU3327 pretreat-
ment markedly reduced the intensity of active p-JNK in CCl4-exposed
mice (third lane). Consistently, SU3327 pretreatment markedly de-
creased the amount of active p-JNK translocated to mitochondria
(Fig. 3D, top panel, third lane) compared with the corresponding
CCl4-exposed mice (second lane). In contrast, the levels of p-ERK in
cytoplasm and mitochondria were unchanged regardless of SU3327
pretreatment (Fig. 3C and D, middle panels, respectively). Conse-
quently, the levels of phosphorylated mitochondrial proteins causallyP-JNK
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Fig. 4. Effects of SU3327 and mito-TEMPO on the levels of lipid peroxides, p-JNK and mitochondrial protein phosphorylation in CCl4-exposed mice. (A) The levels of lipid
peroxides [MDAþHAE] at 24 h post-CCl4 injection without or with SU3327 pretreatment are shown. *, Signiﬁcantly different (po0.05) between the two groups, as indicated.
The Immunoblot results for the levels of (B) active p-JNK and (C) mitochondrial phosphoproteins at 2 h following CCl4 exposure in WT mice without or with mito-TEMPO
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S. Jang et al. / Redox Biology 6 (2015) 552–564 557correlated with the levels of active p-JNK in CCl4-exposed mice in the
absence or presence of SU3327 pretreatment (Fig. 3E).
We also evaluated the effect of SU3327 on the levels of lipid
peroxides as determined by [MDAþHAE]. CCl4 treatment elevated
the levels of [MDAþHAE] (Fig. 4A, second lane) compared to those
of vehicle control (ﬁrst lane) when measured at 24 h, based on the
time-dependent increment of lipid peroxides (Fig. 1C). SU3327
pretreatment signiﬁcantly decreased the levels of lipid peroxides
(third lane). We also investigated the effects of the mitochondria-
targeted antioxidant mito-TEMPO [23] on the levels of activated
p-JNK and phosphorylated mitochondrial proteins. Consistently
with the Fig. 2 results, the levels of active p-JNK and mitochondrial
phosphoproteins (second lanes of Fig. 4B and C, respectively) were
promptly elevated in WT mice exposed to CCl4 for 2 h, compared
to vehicle controls (ﬁrst lanes). Pretreatment with mito-TEMPO
markedly suppressed the levels of p-JNK and phosphoproteins
(third lanes of Fig. 4B and C, respectively), compared to those of
the mice exposed to CCl4 alone (middle lanes in Fig. 4B and C,
respectively). These results suggest the important role of p-JNK
activated at earlier time points in promoting liver injury observed
at later times through protein phosphorylation.
3.4. Identiﬁcation of mitochondrial phosphoproteins
Based on these results with the presence of phosphoproteins in
control mice (Figs. 1–4), we puriﬁed phosphorylated mitochon-
drial proteins respectively from vehicle-control and WT mice ex-
posed to CCl4 for 2 h by using a metal-afﬁnity phosphoprotein
puriﬁcation kit (Qiagen). Subtractive phosphoproteomic analysis
of the mass spectral data with a ratio of CCl4/control groupsgreater than 1.5-fold revealed that at least 106 mitochondrial
proteins were phosphorylated in the CCl4-exposed samples (Ta-
ble 1). As summarized in Fig. 5, many proteins, involved in major
mitochondrial functions such as energy supply, electron transfer,
fatty acid oxidation, anti-oxidant defense, chaperones, amino acid
metabolism, etc, were likely phosphorylated by active p-JNK fol-
lowing CCl4-injection. To systematically evaluate the role of these
mitochondrial proteins in any organ toxicities, we performed
molecular toxicity and pathology enrichment analysis of these
proteins by using MetaCore software. Our analysis revealed that
many of these phosphoproteins are highly associated with liver
toxicity (Supplemental Fig. S3).
3.5. JNK-mediated phosphorylation and activity changes of the se-
lected mitochondrial proteins
To further evaluate the causal roles of phosphoproteins in he-
patotoxicity, we determined the phosphorylation status and ac-
tivity changes in the three randomly-selected proteins ALDH2,
NdufS1 (a 75-kDa subunit of mitochondrial complex I), and α-
KGDH in control and CCl4-exposed mice in the absence or pre-
sence of SU3327 pretreatment. We performed immunoprecipita-
tion by using the speciﬁc antibody against each target protein. The
immunoprecipitated proteins were then subjected to immunoblot
analysis with anti-p-Ser-Pro antibody or antibody against each
protein. Immunoblot results showed that the mitochondrial levels
of ALDH2 remained same regardless of SU3327 pretreatment
(Fig. 6A, top panel). ALDH2, un-phosphorylated in the untreated
control (middle panel, ﬁrst lane), was phosphorylated in
CCl4-exposed mice (second lane), despite the similar levels of
Table 1
Summary of phosphorylated mitochondrial proteins in control and CCl4-exposed mouse livers identiﬁed by mass-spectral analysis. Subtraction of phosphoproteins in control
(CTRL) and CCl4-exposed (EXP) mice was performed as described in the Section 2.3 of Materials and Methods. Only the proteins with the total area ratios greater than 1.5-
fold between EXP and CTRL groups are shown.
Accession Name Description Fold (EXP/
CTRL)
Normalized Intensity_CTRL
(ppm)
Normalized Intensity_EXP
(ppm)
IPI00169916.11 Cltc Clathrin heavy chain 1 137.64 1.11Eþ01 1.53Eþ03
IPI00757372.2 Isoc2a Isochorismatase domain-containing protein 2A,
mitochondrial
49.97 1.50Eþ01 7.48Eþ02
IPI00120212.1 Ndufa9 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex
subunit 9, mito
30.5 1.19Eþ01 3.64Eþ02
IPI00319652.2 Gpx1 Glutathione peroxidase 1 30.37 8.33Eþ01 2.53Eþ03
IPI00454049.4 Echs1 Enoyl-CoA hydratase, mitochondrial 28.25 2.38Eþ02 6.72Eþ03
IPI00468653.4 Pccb Propionyl-CoA carboxylase beta chain, mitochondrial 21.86 6.24Eþ01 1.36Eþ03
IPI00153317.3 Aldh1l1 10-formyltetrahydrofolate dehydrogenase 20.48 3.19Eþ02 6.52Eþ03
IPI00122048.2 Atp1a3 Sodium/potassium-transporting ATPase subunit alpha-3 20.16 1.06Eþ02 2.14Eþ03
IPI00330523.1 Pcca Propionyl-CoA carboxylase alpha chain, mitochondrial 18.75 1.42Eþ02 2.66Eþ03
IPI00133553.1 Mut MethyMethylmalonyl-CoA isomerase, involved in the de-
gradation of several amino acids
18.7 3.40Eþ01 6.36Eþ02
IPI00311682.5 Atp1a1 Sodium/potassium-transporting ATPase subunit alpha-1 15.7 3.95Eþ02 6.21Eþ03
IPI00153660.4 Dlat Acetyltransferase component of pyruvate dehydrogenase
complex
13.88 1.67Eþ02 2.31Eþ03
IPI00471246.2 Ivd Isovaleryl-CoA dehydrogenase, mitochondrial 12.41 1.38Eþ01 1.71Eþ02
IPI00420706.4 Lrpprc Leucine-rich PPR motif-containing protein, mitochondrial 11.07 5.64Eþ02 6.24Eþ03
IPI00122549.1 Vdac1 Isoform Pl-VDAC1 of Voltage-dependent anion-selective
channel protein 1
10.55 1.87Eþ01 1.97Eþ02
IPI00114209.1 Glud1 Glutamate dehydrogenase 1, mitochondrial 9.37 3.57Eþ03 3.34Eþ04
IPI00115302.3 Bckdhb Isoform 2 of 2-oxoisovalerate dehydrogenase subunit beta,
mitochondrial
9.32 1.38Eþ02 1.29Eþ03
IPI00321718.4 Phb2 Prohibitin-2 9.25 6.36Eþ01 5.88Eþ02
IPI00313998.1 Sqrdl Sulﬁde:quinone oxidoreductase, mitochondrial 9.12 7.06Eþ02 6.44Eþ03
IPI00308882.4 Ndufs1 NADH-ubiquinone oxidoreductase 75 kDa subunit,
mitochondrial
9.04 4.34Eþ02 3.92Eþ03
IPI00331564.2 Dld Dihydrolipoyl dehydrogenase 8.88 5.84Eþ01 5.18Eþ02
IPI00121440.4 Etfb Electron transfer ﬂavoprotein subunit beta 8.6 2.91Eþ02 2.50Eþ03
IPI00420882.3 Ogdh Isoform 4 of 2-oxoglutarate dehydrogenase, mitochondrial 8.36 8.06Eþ00 6.73Eþ01
IPI00453499.3 Iars2 Isoleucyl-tRNA synthetase, mitochondrial 8.2 4.77Eþ01 3.91Eþ02
IPI00130081.2 Pex5 Isoform 2 of Peroxisomal targeting signal 1 receptor 7.42 3.76Eþ01 2.79Eþ02
IPI00230138.7 Lyn Isoform LYN B of Tyrosine-protein kinase Lyn 7.39 1.39Eþ02 1.03Eþ03
IPI00469380.3 Aox3 Aldehyde oxidase 1 7.29 2.94Eþ02 2.14Eþ03
IPI00331322.3 Mgst1 Microsomal glutathione S-transferase 1 7.06 1.73Eþ02 1.22Eþ03
IPI00132799.4 C1qbp complement component 1 Q subcomponent-binding protein,
mitochondrial
6.46 1.42Eþ02 9.17Eþ02
IPI00121788.1 Prdx1 Peroxiredoxin 5.91 1.67Eþ02 9.90Eþ02
IPI00676071.3 Mosc1 MOSC domain-containing protein 1, mitochondrial 5.77 1.84Eþ02 1.06Eþ03
IPI00111908.8 Cps1 Carbamoyl-phosphate synthase [ammonia], mitochondrial 5.63 2.39Eþ04 1.34Eþ05
IPI00122862.4 Mthfd1 C-1-tetrahydrofolate synthase, cytoplasmic 5.37 7.54Eþ02 4.05Eþ03
IPI00117312.1 Got2 Aspartate aminotransferase, mitochondrial 5.28 1.18Eþ02 6.23Eþ02
IPI00126625.1 Acsm1 Isoform 1 of Acyl-coenzyme A synthetase ACSM1,
mitochondrial
5.11 2.77Eþ02 1.41Eþ03
IPI00109293.1 Lactb Serine beta-lactamase-like protein LACTB, mitochondrial 5.01 7.79Eþ02 3.90Eþ03
IPI00135651.1 Slc25a13 Calcium-binding mitochondrial carrier protein Aralar2 4.73 5.38Eþ02 2.55Eþ03
IPI00312174.6 Ptges2 Microsomal prostaglandin E synthase 2 4.71 7.45Eþ02 3.50Eþ03
IPI00380320.4 Ldhd Probable D-lactate dehydrogenase, mitochondrial 4.53 9.83Eþ01 4.45Eþ02
IPI00116753.4 Etfa Electron transfer ﬂavoprotein subunit alpha, mitochondrial 4.31 8.15Eþ02 3.51Eþ03
IPI00137194.1 Slc16a1 Monocarboxylate transporter 1 4.26 8.95Eþ01 3.81Eþ02
IPI00115117.1 Stoml2 Stomatin-like protein 2 4.12 5.16Eþ01 2.12Eþ02
IPI00170363.1 Acsl5 Long-chain-fatty-acid-CoA ligase 5 3.89 6.02Eþ02 2.34Eþ03
IPI00319518.4 Lonp1 Lon protease homolog 3.57 1.04Eþ03 3.72Eþ03
IPI00115824.1 Nipsnap1 Protein NipSnap homolog 1 3.3 3.86Eþ02 1.27Eþ03
IPI00117214.3 Hsdl2 Hydroxysteroid dehydrogenase-like protein 2 3.23 2.22Eþ02 7.15Eþ02
IPI00229078.5 Hsd3b4 3-beta-hydroxysteroid dehydrogenase type 4 3.19 2.81Eþ02 8.96Eþ02
IPI00120233.1 Gcdh Glutaryl-CoA dehydrogenase, mitochondrial 2.98 2.61Eþ02 7.78Eþ02
IPI00128286.1 Cyp1a1 Cytochrome P450 1A1 2.95 3.17Eþ02 9.34Eþ02
IPI00320850.3 Mccc1 Methylcrotonoyl-CoA carboxylase subunit alpha
mitochondrial
2.91 4.45Eþ02 1.30Eþ03
IPI00122633.3 Acsf2 Acyl-CoA synthetase family member 2, mitochondrial 2.88 9.05Eþ02 2.61Eþ03
IPI00114710.3 Pcx Pyruvate carboxylase, mitochondrial 2.84 3.57Eþ03 1.01Eþ04
IPI00133903.1 Hspa9 Heat shock 70 kDa protein 9 2.8 7.43Eþ03 2.08Eþ04
IPI00136655.1 Gcat 2-amino-3-ketobutyrate coenzyme A ligase, mitochondrial 2.78 3.48Eþ02 9.68Eþ02
IPI00756386.1 Dhtkd1 2-oxoglutarate dehydrogenase E1 component, mitochondrial 2.78 6.06Eþ02 1.69Eþ03
IPI00330754.1 Bdh1 3-hydroxybutyrate dehydrogenase 2.71 2.44Eþ03 6.60Eþ03
IPI00621548.2 Por NADPH-cytochrome P450 reductase 2.7 1.46Eþ03 3.95Eþ03
IPI00136213.5 Sardh Sarcosine dehydrogenase, mitochondrial 2.68 7.96Eþ01 2.14Eþ02
IPI00379694.4 Hmgcl hydroxymethylglutaryl-CoA lyase, mitochondrial precursor 2.55 1.44Eþ02 3.67Eþ02
IPI00308885.6 Hspd1 Isoform 1 of 60 kDa heat shock protein, mitochondrial 2.54 3.47Eþ03 8.81Eþ03
IPI00139301.3 Krt5 Keratin, type II cytoskeletal 5 2.48 8.53Eþ01 2.12Eþ02
IPI00461964.3 Aldh6a1 Methylmalonate-semialdehyde dehydrogenase, 2.48 2.23Eþ03 5.53Eþ03
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Table 1 (continued )
Accession Name Description Fold (EXP/
CTRL)
Normalized Intensity_CTRL
(ppm)
Normalized Intensity_EXP
(ppm)
mitochondrial
IPI00111218.1 Aldh2 Aldehyde dehydrogenase, mitochondrial 2.38 2.30Eþ03 5.49Eþ03
IPI00223092.5 Hadha Trifunctional enzyme subunit alpha, mitochondrial 2.37 1.72Eþ03 4.06Eþ03
IPI00270326.1 Psmc2 26S protease regulatory subunit 7 2.37 3.80Eþ01 8.99Eþ01
IPI00226140.5 Maob Amine oxidase [ﬂavin-containing] B 2.36 7.37Eþ02 1.74Eþ03
IPI00331436.4 Lap3 Isoform 1 of Cytosol aminopeptidase 2.29 5.99Eþ01 1.37Eþ02
IPI00119114.2 Acadl Long-chain speciﬁc acyl-CoA dehydrogenase, mitochondrial 2.26 8.94Eþ02 2.02Eþ03
IPI00116603.1 Otc Ornithine carbamoyltransferase, mitochondrial 2.23 6.57Eþ02 1.47Eþ03
IPI00132042.1 Pdhb Pyruvate dehydrogenase E1-beta subunit, mitochondrial 2.23 1.32Eþ03 2.96Eþ03
IPI00113052.1 Tsfm Elongation factor Ts, mitochondrial 2.22 1.09Eþ02 2.41Eþ02
IPI00118384.1 Ywhae 14-3-3 protein epsilon 2.21 7.79Eþ02 1.72Eþ03
IPI00331555.2 Bckdha 2-oxoisovalerate dehydrogenase subunit alpha,
mitochondrial
2.17 8.44Eþ03 1.83Eþ04
IPI00322610.5 Coasy Bifunctional coenzyme A synthase 2.15 1.11Eþ02 2.39Eþ02
IPI00132762.1 Trap1 Heat shock protein 75 kDa, mitochondrial 2.14 2.70Eþ03 5.77Eþ03
IPI00322760.7 Prodh Proline dehydrogenase, mitochondrial 2.14 2.35Eþ03 5.03Eþ03
IPI00112549.1 Acsl1 Long-chain speciﬁc acyl-CoA synthetase 1 2.09 4.20Eþ03 8.78Eþ03
IPI00323357.3 Hspa8 Heat shock cognate 71 kDa protein 2.07 2.55Eþ03 5.27Eþ03
IPI00134746.5 Ass1 Argininosuccinate synthase 2.02 1.47Eþ03 2.96Eþ03
IPI00121105.2 Hadh Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial 2.01 1.53Eþ02 3.06Eþ02
IPI00131445.2 Dnm2 Isoform 1 of Dynamin-2 GTPase 1.95 1.89Eþ02 3.70Eþ02
IPI00678532.3 Fam82a2 Regulator of microtubule dynamics protein 3 1.92 1.68Eþ02 3.22Eþ02
IPI00130535.1 Dbt Lipoamide acyltransferase of branched-chain alpha-keto acid
dehydrogenase complex
1.9 1.53Eþ03 2.90Eþ03
IPI00130804.1 Ech1 Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial 1.88 3.75Eþ02 7.07Eþ02
IPI00119203.4 Acadvl Very long-chain speciﬁc acyl-CoA dehydrogenase,
mitochondrial
1.87 3.41Eþ03 6.36Eþ03
IPI00122075.1 Mavs Mitochondrial antiviral-signaling protein 1.86 4.93Eþ02 9.15Eþ02
IPI00134809.2 Dlst Succinyltransferase component of 2-oxoglutarate dehy-
drogenase complex
1.85 4.85Eþ02 8.97Eþ02
IPI00119808.1 Clpx ATP-dependent ClpX-like protease, mitochondrial 1.84 1.06Eþ03 1.95Eþ03
IPI00169862.1 Coq9 Ubiquinone biosynthesis protein COQ9, mitochondrial 1.78 9.68Eþ02 1.73Eþ03
IPI00127841.3 Slc25a5 ADP/ATP translocase 2 1.77 7.18Eþ02 1.27Eþ03
IPI00131177.1 Letm1 LETM1 and EF-hand domain-containing protein 1,
mitochondrial
1.75 1.26Eþ03 2.20Eþ03
IPI00408961.3 Haao 3-hydroxyanthranilate 3,4-dioxygenase 1.73 1.06Eþ02 1.83Eþ02
IPI00387491.1 Aass Alpha-aminoadipic semialdehyde synthase, mitochondrial 1.7 5.45Eþ02 9.27Eþ02
IPI00120123.1 Dmgdh Dimethylglycine dehydrogenase, mitochondrial 1.7 1.07Eþ03 1.82Eþ03
IPI00459487.3 Suclg2 Isoform 1 of Succinyl-CoA ligase subunit beta, mitochondrial 1.69 1.61Eþ03 2.72Eþ03
IPI00135231.2 Idh1 Isocitrate dehydrogenase 1.66 5.24Eþ02 8.70Eþ02
IPI00317074.3 Slc25a10 Mitochondrial dicarboxylate carrier 1.61 1.89Eþ02 3.05Eþ02
IPI00115564.5 Slc25a4 ADP/ATP translocase 1 1.6 7.06Eþ02 1.13Eþ03
IPI00116498.1 Ywhaz 14-3-3 protein zeta/delta 1.58 6.25Eþ02 9.89Eþ02
IPI00127625.1 Hmgcl Hydroxymethylglutaryl-CoA lyase, mitochondrial 1.56 8.03Eþ02 1.25Eþ03
IPI00113886.1 Lmnb2 Lamin B2 isoform 1.55 1.13Eþ03 1.76Eþ03
IPI00110684.1 Ppa1 inorganic pyrophosphatase 1.55 3.81Eþ01 5.92Eþ01
IPI00130280.1 Atp5a1 ATP synthase subunit alpha, mitochondrial 1.53 1.51Eþ04 2.32Eþ04
IPI00230108.6 Pdia3 Protein disulﬁde-isomerase A3 1.53 4.26Eþ03 6.52Eþ03
IPI00113869.1 Bsg Isoform 2 of Basigin 1.53 1.47Eþ02 2.24Eþ02
IPI00119842.1 Acadsb Short/branched chain acyl-CoA dehydrogenase,
mitochondrial
1.53 8.58Eþ01 1.32Eþ02
S. Jang et al. / Redox Biology 6 (2015) 552–564 559immunoprecipitated ALDH2 protein for each lane (bottom panel).
However, the intensity of phosphorylated ALDH2 was markedly
reduced upon SU3327 pretreatment (middle panel, third lane),
suggesting reversible phosphorylation of ALDH2, depending on
the JNK activity. Consistently, the ALDH2 activity in the mi-
tochondrial extracts was signiﬁcantly suppressed in WT mice ex-
posed to CCl4 for 2 h compared to the control group, but its sup-
pressed activity was restored in SU3327-pretreated mice (Fig. 6B).
In addition, the levels of NdufS1 were similar in differently-
treated mice regardless of SU3327 pretreatment (Fig. 6C, top pa-
nel). NdufS1 phosphorylation was markedly increased in
CCl4-exposed WT mice (middle panel, second lane), compared to
the untreated control (ﬁrst lane). The intensity of the phos-
phorylated protein band was markedly reduced in SU3327-pre-
treated mice (third lane). Consistently, the mitochondrial complex
I activity was signiﬁcantly decreased in CCl4-exposed WT mice
compared with those of control (Fig. 6D). Furthermore, the de-
creased activity was restored in the SU3327-pretreated group.Similar patterns of reversible phosphorylation (Fig. 6E) and
activity change (Fig. 6F) in α-KGDH were observed in CCl4-exposed
mice in the absence or presence of SU3327. These results (Fig. 6)
not only substantiate the presence of phosphoproteins determined
by mass spectrometry but also support that JNK-mediated phos-
phorylation of certain mitochondrial proteins is responsible for the
suppressed activities at 2 h, contributing to CCl4-induced mi-
tochondrial dysfunction and liver injury observed at later time
points (e.g., at 24 h as shown in Fig. 1).
Activated p-JNK can phosphorylate pro-apoptotic Bax to pro-
mote mitochondrial permeability transition (MPT) change and cell
damage [15,38]. Our results showed that time-dependent mi-
tochondrial translocation of Bax and subsequent release of cyto-
chrome C were maximal at 2 h post-CCl4 injection (Fig. 7A).
However, these events were signiﬁcantly blocked by the SU3327
treatment (Fig. 7B). Consistently, CCl4 exposure signiﬁcantly in-
creased time-dependent mitochondrial swelling (Fig. 7C), which
was signiﬁcantly prevented by SU3327 pretreatment (Fig. 7D),
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Fig. 5. Summary of phosphorylated mitochondrial proteins in WT mice exposed to CCl4 for 2 h. Various functions of mitochondrial proteins that were phosphorylated in
CCl4-exposed mouse liver and identiﬁed by mass spectrometry are summarized. The activities of the three proteins marked in blue and bold characters were suppressed in
CCl4-exposed mice compared to the corresponding vehicle-controls. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web
version of this article.)
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function, prior to hepatotoxicity.4. Discussion
Molecular mechanisms of acute liver injury caused by many
compounds including FDA-approved drugs such as APAP and tro-
glitazone, an anti-diabetic agent, have been actively studied be-
cause of severe mitochondrial dysfunction and hepatotoxicity [1–
4,39–43]. Many abused substances including cocaine and amphe-
tamine derivatives are also known to cause mitochondrial dys-
function and acute hepatotoxicity [44,45] especially in people who
drink alcohol [44]. From the experimental models, many different
mechanisms have been proposed to explain the acute hepato-
toxicity. These mechanisms include: production of reactive meta-
bolites and protein adducts, increased oxidative/nitrative stress,
protein modiﬁcations and subsequent mitochondrial dysfunction,
lipid peroxidation, inﬂammation through activation of innate im-
mune responses, toxic ceramide production, activation of the cell
death pathways, suppression of the cell proliferation/survival
pathway, etc. [45–48]. In general, all these mechanisms work to-
gether toward tissue injury, as recently discussed [47,48].
Activation of JNK alone or in combination with p38K is re-
sponsible for promoting cell death [10,11]. Other laboratories and
we reported the critical role of JNK activation in drug-induced
acute hepatotoxicity [12–15,37–39] and ischemia-reperfusion in-
jury [16]. Although JNK was the main MAPK activated by CCl4
exposure [17,36] and in our current study (Figs. 1 and 3), another
report suggested that activated JNK did not seem to be critical in
CCl4-mediated liver injury through evaluation with the ATP-com-
petitive JNK inhibitor SP600125 and the JNK peptide inhibitor-1
(D-JNKI-1), which interferes with the interaction between JNK and
its substrates [13]. The negative role of JNK in CCl4-relatedhepatotoxicity [13] could result from: (1) the additional activity of
SP600125 and its non-speciﬁc inhibition of other protein kinases
[49–52]; (2) potential compensatory mechanisms between the
JNK1 and JNK2 isoforms in the liver; (3) potential toxicity of
SP600125 by itself in some cases [53]; (4) a relatively high dosage
of CCl4 in a different mouse strain used for the previous study [13]
compared to this current study; and (5) no usage of other selective
JNK inhibitors such as SU3327 and BI-78D3 [20–22]. Furthermore,
to our knowledge, the identities and functional roles of mi-
tochondrial phosphoprotein targets of active p-JNK have never
been studied systematically. Therefore, in the current study, we
aimed to re-evaluate the role of JNK in promoting liver injury
caused by CCl4, as a model of acute hepatotoxicity, by carefully
studying the time-dependent JNK activation and the levels of its
mitochondrial phosphoprotein targets, lipid peroxides and liver
injury with two newly-developed highly-speciﬁc JNK inhibitors
SU33327 [20] and BI-78D3 [21,22]. Since APAP can cause liver
injury by promoting protein nitration [54,55] in addition to JNK-
mediated protein phosphorylation [12,13], we intentionally chose
to use CCl4 in this study to re-investigate the roles of JNK activa-
tion and JNK-mediated protein phosphorylation at early time
points prior to mitochondrial dysfunction and acute liver injury,
based on the relatively selective activation of JNK by CCl4 [17,36].
We now provide evidence that p-JNK activated at earlier time
points plays a pivotal role in promoting CCl4-induced mitochon-
drial dysfunction and hepatotoxicity through phosphorylation of
many mitochondrial proteins and inactivation of their functions.
However, these events were markedly reduced in the presence of
the two new JNK-speciﬁc inhibitors SU3327 (Figs. 3, 4 and 6) and
BI-78D3 (not shown). Furthermore, neither JNK activation nor
hepatotoxicity was observed in CCl4-exposed Cyp2e1-null mice
despite the same treatment of CCl4 (Fig. 2). We also showed that
prompt JNK activation, translocation of active p-JNK to mi-
tochondria, and protein phosphorylation likely represent the
Fig. 6. Selected mitochondrial proteins are phosphorylated and their activities suppressed by p-JNK. (A) The level of mitochondrial ALDH2 in control and CCl4-exposed WT
mice in the absence or presence of SU3327 pretreatment was determined by immunoblot analysis (top panel). Mitochondrial proteins (0.5 mg/analysis) from vehicle-control
and mice exposed to CCl4 for 2 h in the absence or presence of SU3327 were immunoprecipitated with anti-ALDH2 antibody and then subjected to immunoblot analysis with
anti-p-Ser-Pro antibody (middle) or anti-ALDH2 antibody (bottom). (B) ALDH2 activity in mitochondrial extracts (0.1 mg protein/assay) for the indicated groups with or
without SU3327 pretreatment was determined. Additional analyses were conducted on NdufS1 (complex I) (C, D) and α-KGDH (E, F), as indicated. *, Signiﬁcantly different
(po0.05) from the other groups.
S. Jang et al. / Redox Biology 6 (2015) 552–564 561critical events in CCl4-mediated hepatotoxicity than lipid perox-
idation [5,6], nitrative stress [54,55], and TNFα-associated in-
ﬂammation, as previously suggested [13,35], since these latter
factors were elevated only at 24 h post-CCl4 exposure (Fig. 1 and
data not shown). Based on these time-dependent observations, we
believe that lipid peroxidation and inﬂammation likely reﬂect the
consequences rather than the causes of hepatotoxicity. Further-
more, the results with Cyp2e1-null mice (Fig. 2) and mito-TEMPO
(Fig. 4) indicate that CYP2E1-mediated CCl4 metabolism induces
oxidative stress, which can rapidly activate JNK (Fig. 2) resulting
from inhibition of MAPK phosphatases through oxidative mod-
iﬁcations of their active site Cys and other critical Cys residues,
as recently reviewed [48]. Activated p-JNK then transloc-
ates to mitochondria and phosphorylates many proteins includ-ing mitochondrial complex I, resulting in suppression of the mi-
tochondrial electron transport chain, and thus markedly elevating
oxidative stress, which ultimately contributes to mitochondrial
dysfunction and hepatotoxicity with increased lipid peroxidation
observed at later time points.
In addition, JNK was reported to promote cell death through
phosphorylating Bax, which contributes to mitochondrial permeability
transition (MPT) change (swelling) and apoptosis [15, 39]. It is well-
established that activated p-JNK translocates to mitochondria upon
exposure to various toxic stimulants such as staurosporine, ionizing
radiation, UV [15] and anisomycin [56]. Hanawa et al. reported that
activated p-JNK was translocated to mitochondria to induce MPT and
inhibit mitochondrial respiration, leading to acute hepatocyte injury in
APAP-exposed mice [39]. Our previous report also showed that p-JNK
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where it could phosphorylate mitochondrial ALDH2 [18]. However, to
our knowledge, the JNK-target proteins in mitochondria are poorly
understood, although PDH E1α and β subunits, Hsp60 and ATP syn-
thase were phosphorylated by active p-JNK in an in vitro system [19].
Therefore, another aim of this study was to systematically identify
mitochondrial target proteins that are phosphorylated by p-JNK and
study their contributing roles in CCl4-related mitochondrial dysfunc-
tion and hepatotoxicity. By using mass-spectral analysis of the afﬁnity-
puriﬁed phosphoproteins (with more than 2 different peptides iden-
tiﬁed by mass spectrometry) and using subtraction phospho-pro-
teomics with the ratio of CCl4/control greater than 1.5, we found that
at least 106 mitochondrial proteins, including ALDH2,
NADþ-ubiquinone-dehydrogenase, α-KGDH, etc were likely phos-
phorylated (Table 1). Although our result also conﬁrmed the small list
of JNK-target phosphoproteins from the in vitro experiment [19], we
believe that the actual number of JNK-target proteins in mitochondria
could be a lot more than what we identiﬁed in this study, since the
JNK-target proteins existing in small amounts, such as Bax [15] and
Sab [57,58], may not be detected due to the detection limit of our
mass-spectral analysis. Despite this disadvantage, by using im-
munoprecipitation followed by immunoblot with anti-phospho-Ser-
Pro antibody, we conﬁrmed JNK-mediated phosphorylation of the
three selected target proteins in CCl4-exposed mice. Furthermore, we
demonstrate the functional roles of some of the phosphoproteins since
the suppressed activities of these proteins were restored by JNK in-
hibitor SU3327 pretreatment. We expect that the activities of other
phosphorylated proteins in CCl4-exposed mice could be also modu-
lated through JNK-mediated phosphorylation.
The mechanisms of CCl4-induced mitochondrial dysfunction
have not been fully understood despite previous efforts [5,6 and
references within]. Based on our results of the suppressedactivities of phosphorylated mitochondrial proteins despite similar
protein levels (Fig. 6), post-translational modiﬁcations of mi-
tochondrial proteins by p-JNK activated at earlier time points
(Fig. 2) are at least partially responsible for CCl4-induced mi-
tochondrial dysfunction prior to hepatotoxicity. Our results
showed that α-KGDH and complex I, involved in cell energy sup-
ply, were suppressed in CCl4-exposed tissues compared to control.
ALDH2, involved in anti-oxidant defense, was also suppressed
following CCl4 exposure. Since JNK activation and phosphorylation
occurred earlier (e.g., 1 or 2 h) and led to inactivation of ALDH2,
complex I, and α-KGDH, their suppression was likely to promote
mitochondrial dysfunction, contributing to increased MPT [38],
and eventually liver injury observed at 24 h post-injection. Al-
though we have not tested many other phosphoproteins, it is likely
that the activities of some of the phosphorylated mitochondrial
proteins may be modulated in a JNK-dependent manner. Thus, our
current study provides a novel mechanism for CCl4-induced mi-
tochondrial dysfunction and hepatotoxicity through JNK-mediated
phosphorylation of many mitochondrial proteins
Although we have puriﬁed and identiﬁed phosphorylated mi-
tochondrial proteins by mass-spectral analysis, we do not know
speciﬁc phosphorylation sites yet. The canonical JNK binding motif
sequence is: R/K2–3-X1–6-L/I-X-L/I [59]. Based on the comparative
sequence analysis between mitochondrial ALDH2 and cytosolic
ALDH1, we reported that 463Ser-Pro of ALDH2 could be the prime
site of JNK-mediated phosphorylation [18]. We also observed that
75 kDa-subunit NdufS1 subunit of complex I was phosphorylated
after CCl4 exposure. This protein also contains one putative JNK
binding site at 515K-R-N-P-P-K-M-L-F-L, and four potential phos-
phorylation sites (Ser411-Pro, Ser425-Pro, Thr588-Pro, Ser627-Pro) by
active p-JNK. Sequence analysis revealed that α-KGDH contains
one canonical JNK binding motif at 376K-K-V-M-S-I-L-L, and eight
S. Jang et al. / Redox Biology 6 (2015) 552–564 563potential phosphorylation sites (Ser55-Pro, Thr215-Pro, Ser433-Pro,
Ser562-Pro, Ser711-Pro, Thr809-Pro, Thr833-Pro, Ser909-Pro) by p-JNK.
However, the exact sites of phosphorylation in these proteins re-
main to be established.
In conclusion, by studying temporal changes in JNK activation,
lipid peroxidation, pro-inﬂammatory TNF-α levels and histological
liver damage following CCl4 administration, we demonstrated the
critical role of JNK activation and subsequent protein phosphor-
ylation in chemical-induced mitochondrial dysfunction and acute
hepatotoxicity. We have afﬁnity-puriﬁed phosphorylated mi-
tochondrial proteins from CCl4-exposed mouse liver and control
tissues and determined their identities by mass-spectral analysis.
Our results revealed that many mitochondrial proteins were
phosphorylated by p-JNK and that their cellular functions could be
altered, contributing to mitochondrial dysfunction and hepato-
toxicity. By using two new JNK-speciﬁc inhibitors SU3327 and BI-
78D3, which potently blocked JNK without affecting ERK activity,
we also showed that the activities of the selected phosphorylated
mitochondrial proteins and hepatotoxicity were reversibly
modulated in a JNK-dependent manner, suggesting a causal re-
lationship between JNK-mediated phosphorylation of mitochon-
drial proteins and their functions. These data demonstrate for the
ﬁrst time an important role of JNK-mediated phosphorylation of
many mitochondrial proteins in promoting chemical-induced mi-
tochondrial dysfunction and acute liver injury.Disclosure
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